AADI aadibio.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Aadi Bioscience (AADI) develops targeted drugs to combat tumors. This chart illustrating the price evolution confirms the impact of Fyarro sales on margins, with EV/EBITDA standing at . The company minimizes costs by outsourcing drug synthesis and testing to external contractors. Due to the humanitarian status of the medicine, the business is shielded from sanctions and global political upheavals, maintaining operational resilience.

This multiple relates the total enterprise value, including debt, to its operating profit before taxes and depreciation and amortization. This metric determines the real value of the asset by excluding the impact of debt load and the tax regime. Analyzing the business valuation of Aadi Bioscience (AADI) through EV/EBITDA trends is critically important, as high R&D costs and strict FDA oversight impact capitalization.